Opendata, web and dolomites

StopAddict SIGNED

The game changer drug to cure alcohol use disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StopAddict project word cloud

Explore the words cloud of the StopAddict project. It provides you a very rough idea of what is the project "StopAddict" about.

granted    first    therapies    mechanism    adjusted    2027    expenses    uncontrolled    pharma    smei2    stopaddict    ip    283    10    award    situation    deals    70    man    generating    poor    successful    132    kt    mise    alcoholism    newly    aud    families    disability    jobs    damaging    actions    burden    kinnov    accepted    patient    efficacy    persons    2025    create    fto    therapeutics    french    direct    companies    suffer    agency    revenues    clinical    patients    class    dead    continuous    worldwide    billion    decreasing    triple    consumption    life    110    achievement    society    million    400    seeking    implicated    revolutionary    117m    indirect    unsuccessful    treatments    cumulative    alcohol    intensive    people    neuropsychopharmacology    recovery    licensing    leader    save    2018    context    action    2009    treatment    drug    disorders    college    leads    huge    regulatory    social    communities    discovered    updated    commercialisation    trial    addiction    characterised    lives    disease   

Project "StopAddict" data sheet

The following table provides information about the project.

Coordinator
KINNOV THERAPEUTICS 

Organization address
address: 3 ALLEE DU TITANE
city: Orleans
postcode: 45100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙432˙400 €
 EC max contribution 2˙402˙680 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KINNOV THERAPEUTICS FR (Orleans) coordinator 2˙402˙680.00

Map

 Project objective

Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPADDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPADDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More